Preclinical Pharmacokinetics and Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment

Overview

Journal Front Pharmacol

Date 2022 Sep 2

PMID 36052127

Authors

Amy Q Wang

Natalie R Hagen

Elias C Padilha

Mengbi Yang

Pranav Shah

Catherine Z Chen

Wenwei Huang

Pramod Terse

Philip Sanderson

Wei Zheng

Xin Xu

Affiliations

Soon will be listed here.

Abstract

Preclinical pharmacokinetics (PK) and ADME properties of GS-441524, a potential oral agent for the treatment of Covid-19, were studied. GS-441524 was stable in liver microsomes, cytosols, and hepatocytes of mice, rats, monkeys, dogs, and humans. The plasma free fractions of GS-441524 were 62-78% across all studied species. The transporter study results showed that GS-441524 was a substrate of MDR1, BCRP, CNT3, ENT1, and ENT2; but not a substrate of CNT1, CNT2, and ENT4. GS-441524 had a low to moderate plasma clearance (CL), ranging from 4.1 mL/min/kg in dogs to 26 mL/min/kg in mice; the steady state volume distribution (Vd) ranged from 0.9 L/kg in dogs to 2.4 L/kg in mice after IV administration. Urinary excretion appeared to be the major elimination process for GS-441524. Following oral administration, the oral bioavailability was 8.3% in monkeys, 33% in rats, 39% in mice, and 85% in dogs. The PK and ADME properties of GS-441524 support its further development as an oral drug candidate.

Citing Articles

First analytical confirmation of drug-induced crystal nephropathy in felines caused by GS-441524, the active metabolite of Remdesivir.

Furbish A, Allinder M, Austin G, Tynan B, Byrd E, Gomez I J Pharm Biomed Anal. 2024; 247:116248.

PMID: 38823223 PMC: 11229044. DOI: 10.1016/j.jpba.2024.116248.

Antiviral drug recognition and elevator-type transport motions of CNT3.

Wright N, Zhang F, Suo Y, Kong L, Yin Y, G Fedor J Nat Chem Biol. 2024; 20(9):1144-1153.

PMID: 38418906 PMC: 11625470. DOI: 10.1038/s41589-024-01559-8.

Uroliths composed of antiviral compound GS-441524 in 2 cats undergoing treatment for feline infectious peritonitis.

Allinder M, Tynan B, Martin C, Furbish A, Austin G, Bartges J J Vet Intern Med. 2023; 38(1):370-374.

PMID: 38032049 PMC: 10800210. DOI: 10.1111/jvim.16954.

Molnupiravir Revisited-Critical Assessment of Studies in Animal Models of COVID-19.

Rasmussen H, Hansen P Viruses. 2023; 15(11).

PMID: 38005828 PMC: 10675540. DOI: 10.3390/v15112151.

Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.

Mackman R, Kalla R, Babusis D, Pitts J, Barrett K, Chun K J Med Chem. 2023; 66(17):11701-11717.

PMID: 37596939 PMC: 11556372. DOI: 10.1021/acs.jmedchem.3c00750.

References

Mai Y, Dou L, Yao Z, Madla C, Gavins F, Taherali F . Quantification of P-Glycoprotein in the Gastrointestinal Tract of Humans and Rodents: Methodology, Gut Region, Sex, and Species Matter. Mol Pharm. 2021; 18(5):1895-1904. PMC: 8289313. DOI: 10.1021/acs.molpharmaceut.0c00574. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Xia C, Xiao G, Liu N, Pimprale S, Fox L, Patten C . Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays. Mol Pharm. 2006; 3(1):78-86. DOI: 10.1021/mp050034j. View

Takahashi K, Yoshisue K, Chiba M, Nakanishi T, Tamai I . Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine. Biopharm Drug Dispos. 2017; 39(1):38-46. DOI: 10.1002/bdd.2110. View

Morote-Garcia J, Rosenberger P, Nivillac N, Coe I, Eltzschig H . Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology. 2008; 136(2):607-18. DOI: 10.1053/j.gastro.2008.10.037. View

Sun H, Nguyen K, Kerns E, Yan Z, Yu K, Shah P . Highly predictive and interpretable models for PAMPA permeability. Bioorg Med Chem. 2017; 25(3):1266-1276. PMC: 5291813. DOI: 10.1016/j.bmc.2016.12.049. View

Sharma V, McNeill J . To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol. 2009; 157(6):907-21. PMC: 2737649. DOI: 10.1111/j.1476-5381.2009.00267.x. View

Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T . Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J Pharm Sci. 2006; 95(12):2673-83. DOI: 10.1002/jps.20686. View

Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L . Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother. 2020; 75(10):2977-2980. PMC: 7337789. DOI: 10.1093/jac/dkaa239. View

10.

Owen D, Allerton C, Anderson A, Aschenbrenner L, Avery M, Berritt S . An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19. Science. 2021; 374(6575):1586-1593. DOI: 10.1126/science.abl4784. View

11.

Warren T, Jordan R, Lo M, Ray A, Mackman R, Soloveva V . Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531(7594):381-5. PMC: 5551389. DOI: 10.1038/nature17180. View

12.

Shah P, Siramshetty V, Zakharov A, Southall N, Xu X, Nguyen D . Predicting liver cytosol stability of small molecules. J Cheminform. 2021; 12(1):21. PMC: 7140498. DOI: 10.1186/s13321-020-00426-7. View

13.

Miller S, McGrath M, Zorn K, Ekins S, Wright S, Cherrington N . Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. Mol Pharmacol. 2021; 100(6):548-557. PMC: 8626781. DOI: 10.1124/molpharm.121.000333. View

14.

Yan V, Muller F . Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. ACS Med Chem Lett. 2020; 11(7):1361-1366. PMC: 7315846. DOI: 10.1021/acsmedchemlett.0c00316. View

15.

Chen C, Shinn P, Itkin Z, Eastman R, Bostwick R, Rasmussen L . Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Front Pharmacol. 2021; 11:592737. PMC: 7942396. DOI: 10.3389/fphar.2020.592737. View

16.

Mahmood I, Balian J . Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica. 1996; 26(9):887-95. DOI: 10.3109/00498259609052491. View

17.

Sun H, Shah P, Nguyen K, Yu K, Kerns E, Kabir M . Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity. Bioorg Med Chem. 2019; 27(14):3110-3114. PMC: 8274818. DOI: 10.1016/j.bmc.2019.05.037. View

18.

Gottlieb R, Vaca C, Paredes R, Mera J, Webb B, Perez G . Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2021; 386(4):305-315. PMC: 8757570. DOI: 10.1056/NEJMoa2116846. View

19.

Goldman J, Lye D, Hui D, Marks K, Bruno R, Montejano R . Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020; 383(19):1827-1837. PMC: 7377062. DOI: 10.1056/NEJMoa2015301. View

20.

Siegel D, Hui H, Doerffler E, Clarke M, Chun K, Zhang L . Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017; 60(5):1648-1661. DOI: 10.1021/acs.jmedchem.6b01594. View